You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • AB0248 Clinical Significance of Soluble Vascular Endothelial-Cadherin and Anti-Vascular Endothelial-Cadherin Antibody in Rheumatoid Arthritis Treated with Etanercept or Adalimumab

Alerts

Article menu
Download PDFPDF
Abstracts Accepted for Publication
Rheumatoid arthritis - prognosis, predictors and outcome
AB0248 Clinical Significance of Soluble Vascular Endothelial-Cadherin and Anti-Vascular Endothelial-Cadherin Antibody in Rheumatoid Arthritis Treated with Etanercept or Adalimumab
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address